CSF1R and neoplasm: Targeting TAM-associated pathways, such as CSF-1R and CCR2, with AMG820 and PF-04136309 antibodies, respectively, can reprogram TAMs toward a pro-inflammatory M1 phenotype, supporting anti-tumor immunity [87].